PharmiWeb Today Story
BioNTech has announced the acquisition of fellow German biotech CureVac in an all-stock transaction valued at approximately $1.25 billion. Under the agreement, CureVac shareholders will receive about $5.46 in BioNTech American Depositary Shares (ADS) for each CureVac share, representing a 55% premium over CureVac’s recent share price.
This strategic move aims to bolster BioNTech's capabilities in developing mRNA-based cancer immunotherapies, reflecting its long-term focus on oncology beyond its COVID-19 vaccine success in partnership with Pfizer. The acquisition will also resolve ongoing patent disputes between the two companies, including a significant case involving mRNA technology.
CureVac, headquartered in Tübingen, Germany, had previously shifted its focus towards cancer treatment, exiting flu and COVID-19 vaccine development through a deal with GSK after its initial COVID-19 vaccine candidate showed limited efficacy in clinical trials. The integration of CureVac's research and manufacturing facilities is expected to enhance BioNTech's production capacity and accelerate the development of next-generation mRNA therapies.
The transaction is anticipated to close later in 2025, pending regulatory approvals and shareholder acceptance. Post-acquisition, CureVac shareholders are expected to own between 4% and 6% of BioNTech.
Read More...
Articles

Top Interview Questions for Medical Writing Jobs
11-Jun-2025

What Does a Pharmaceutical Account Manager Do?
04-Mar-2025

Top 10 Highest Paying Pharma Jobs in 2025
18-Feb-2025

The Impact of AI on Pharmaceutical Sales
13-Feb-2025
Featured Events

-
6th CAR-TCR Summit
30-Aug-2021 - 02-Sep-2021 -
Reuters Events: Pharma 2021
11-Oct-2021 - 22-Oct-2021 -
HFpEF Drug Discovery & Development Summit 2022
25-Jan-2022 - 27-Jan-2022 -
AI in Healthcare Summit Boston 2022
13-Oct-2022 - 14-Oct-2022 -
Genomics and Precision Medicine Expo
23-May-2023 - 24-May-2023 -
Global Biomanufacturing Summit
25-May-2023 - 26-May-2023
News

-
Former MetroHealth CEO Dr. Airica Steed on Buildin…
01-Jul-2025 -
Luxora Experiences Expands Its Cross-Border Medica…
01-Jul-2025 -
How Our Bodies Respond to Acute and Chronic Pain R…
01-Jul-2025 -
New Horizon Medical Solutions Adds AmchoPlast(TM)…
01-Jul-2025 -
ASTCT’s Leadership Contributes to FDA Decision to…
01-Jul-2025 -
Enzyme Replacement Therapy for Pompe Disease Marke…
01-Jul-2025